Department of Neurology, Renmin Hospital of Wuhan University, Hubei General Hospital, Wuhan, Hubei, China.
Department of Neurology, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Neurosci Lett. 2021 Feb 6;745:135626. doi: 10.1016/j.neulet.2021.135626. Epub 2021 Jan 10.
Anxiety disorder is a common non-motor symptom in patient with Parkinson's disease (PD). We aimed to explore its pathogenesis and identify plasma biomarkers using untargeted metabolomics analysis.
Consecutive PD patients and healthy controls were recruited. Clinical data were assessed and patients with Parkinson's disease related anxiety disorder (PDA) were recognized. Fast plasma samples were obtained and untargeted liquid chromatography-mass spectrometry-based metabolomics analysis was performed. Based on the differentially expressed metabolites from the above metabolomics analysis, correlation analyses and receiver operating characteristic curves (ROC) were further employed.
According to the clinical data, PDA patients had lower plasma levels of total cholesterol, triglyceride, low-density lipoprotein cholesterol, and apolipoprotein B. There were thirty-nine differentially expressed metabolites in PDA patients when compared with the other two groups from the metabolomics analysis, respectively. Fourteen lipid metabolites were simultaneously altered between these two groups, and all of them were significantly decreased. They can be further subcategorized into fatty acyls, glycerolipids, sterol lipids, sphingolipids, and prenol lipids. The plasma levels of thirteen metabolites were negatively correlated with HAMA scores except 10-oxo-nonadecanoic acid. Based on the ROC curves, the fourteen lipid metabolites can be diagnostic biomarkers for PDA patients separately and the areas under the curve of the fourteen lipid metabolites ranged from 0.681 to 0.798.
Significantly lower plasma lipoproteins can be found in PDA patients. A panel of fourteen lipid metabolites were also significantly decreased and can be clinical biomarkers for the diagnosis of PDA patients.
焦虑障碍是帕金森病（PD）患者常见的非运动症状。我们旨在通过非靶向代谢组学分析探讨其发病机制并确定血浆生物标志物。
连续招募 PD 患者和健康对照者。评估临床数据，并识别出帕金森病相关焦虑症（PDA）患者。快速采集血浆样本并进行基于非靶向液相色谱-质谱联用的代谢组学分析。基于上述代谢组学分析中的差异表达代谢物，进一步进行相关性分析和受试者工作特征曲线（ROC）分析。
根据临床数据，PDA 患者的总胆固醇、甘油三酯、低密度脂蛋白胆固醇和载脂蛋白 B 血浆水平较低。与其他两组相比，PDA 患者的代谢组学分析中有 39 种差异表达的代谢物。这两组之间同时改变了 14 种脂质代谢物，它们均显著降低。它们可以进一步细分为脂肪酸酰基、甘油酯、甾醇脂质、神经鞘脂和prenol 脂质。除了 10-氧代-十九烷酸外，除了 HAMA 评分外，这 13 种代谢物的血浆水平与 HAMA 评分呈负相关。基于 ROC 曲线，这 14 种脂质代谢物可以分别作为 PDA 患者的诊断生物标志物，而这 14 种脂质代谢物的曲线下面积范围为 0.681 至 0.798。
PDA 患者的血浆脂蛋白水平明显降低。一组 14 种脂质代谢物也明显降低，可作为 PDA 患者诊断的临床生物标志物。
